Evidence map›Paper›PMID 40639350›Full record

ArticleRespiration; international review of thoracic diseases2025

Baricitinib for Acute Exacerbation in Idiopathic Interstitial Pneumonias: A Preliminary Study Using Propensity Score Matching.

Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Moe Nomaki, Rie Kawabe, Chisa Uzuka, Hiroki Sasaki, Masako Amano, Tamiko Takemura and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiration; international review of thoracic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hideaki YamakawaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Shintaro SatoDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Hiroki OhtaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Kenji KusanoDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Moe NomakiDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Rie KawabeDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Chisa UzukaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Hiroki SasakiDepartment of Radiology, Saitama Red Cross Hospital, Saitama, Japan.
Masako AmanoDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Tamiko TakemuraDepartment of Pathology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Jun ArayaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Hidekazu MatsushimaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Background and Objective: Acute exacerbation of interstitial lung disease (AE-ILD) is a life-threatening complication for which there are only limited treatment options, with essentially no established treatment options. Janus kinase (JAK) inhibitors, such as baricitinib, have recently emerged as potential therapeutic candidates for severe and progressive forms of ILD. This study aimed to evaluate the efficacy and safety of baricitinib in patients with AE-ILD associated with idiopathic interstitial pneumonias (IIPs).

methodsThis retrospective cohort study included patients with IIPs who experienced AE-ILD and were admitted to a single tertiary care center. Patients treated with baricitinib (December 2022 to June 2024) were compared with historical controls (January 2021-November 2022). Propensity score matching (PSM) was conducted using age, PaO

resultsAfter PSM, 17 patients were analyzed in each group. The 90-day survival rate in the baricitinib group (82.4%) was significantly higher than in the control group (52.9%, p = 0.049), while longer term survival did not differ to a statistically significant extent. Baricitinib was well tolerated, with only mild adverse events observed. A trend toward improved 90-day survival was also noted with anti-fibrotic therapy administered during AE-ILD (p = 0.089).

conclusionsBaricitinib may improve short-term survival in AE-ILD and was well tolerated in the acute phase. Its dual JAK1/2 inhibition suggests both anti-inflammatory and anti-fibrotic potential. Further prospective studies are needed to confirm these findings and explore combination therapies. </p>.

Indexed as

AzetidinesIdiopathic Interstitial PneumoniasJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesAgedDisease ProgressionFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesSurvival RateTreatment OutcomeAzetidinesbaricitinibJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesAcute exacerbationBaricitinibInterstitial lung diseaseJanus kinase inhibitorsPrognosis

Identifiers

PMID40639350
PMCPMC12503432

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.